Three years ago, cancer immunotherapy was the hottest thing in biotech, as Dendreon Corporation (NASDAQ:DNDN)'s Provenge earned approval from the Food and Drug Administration ...
Keep Reading →
September 12 - News - Comments
I know it's like comparing apples and oranges, but humor me for a moment.
Keep Reading →
September 11 - News - Comments
Last November, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing that deep-value...
Keep Reading →
September 6 - News - Comments
To the average investor, there are tons of methods shareholders can use to monitor the equity markets.
Keep Reading →
September 5 - News - Comments
To many market players, hedge funds are perceived as delayed, old financial tools of a period lost to current times.
Keep Reading →
September 3 - News - Comments
To the average investor, there are dozens of indicators market participants can use to analyze their holdings.
Keep Reading →
August 30 - News - Comments
Last November, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing that deep-value...
Keep Reading →
August 30 - News - Comments
Since Dendreon Corporation (NASDAQ:DNDN) reported its second-quarter earnings, the stock has declined 40%.
Keep Reading →
August 28 - News - Comments
Johnson & Johnson (NYSE:JNJ) completed its acquisition of privately held Aragon Pharmaceuticals earlier this week. Plans for the deal were first announced by J&J in June.
Keep Reading →
August 23 - News - Comments
Nine months into running the real-money portfolio I manage for The Motley Fool, I invested a small amount in Dendreon Corporation (NASDAQ:DNDN), seller of prostate cancer treatment...
Keep Reading →
August 19 - News - Comments
If you've ever taken the time to really follow the biopharmaceutical sector, you know very well that failures are a dime a dozen, and success stories are few and far between.
Keep Reading →
August 19 - News - Comments
Last November, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing that deep-value...
Keep Reading →
August 13 - News - Comments
August might be hot for most of the country, but the first full week of the month wasn't so hot for some stocks.
Keep Reading →
August 12 - News - Comments
Let's start with Allied Nevada Gold Corp. (NYSEMKT:ANV).
Keep Reading →
August 12 - News - Comments
Today, let's look at Graham Capital Management, founded in 1994 by Ken Tropin and in the multistrategy macro-oriented hedge fund business.
Keep Reading →
August 9 - News - Comments
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Keep Reading →
August 7 - News - Comments
Last November, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing that deep-value...
Keep Reading →
August 2 - News - Comments
There are many types of biotech companies out there with tremendous value. Today, I will focus on the ones that target prostate cancer.
Keep Reading →
August 1 - News - Comments
Last November, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing that deep-value...
Keep Reading →
July 28 - News - Comments
Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at $500 million or more written...
Keep Reading →
July 24 - News - Comments
There’s a lot to notice from Johnson & Johnson (NYSE:JNJ)’s earnings -- the company announced a very solid quarter.
Keep Reading →
July 17 - News - Comments
A year ago, AVI BioPharma underwent a process from being an $85 million biotechnology company to a $1.3 billion company called Sarepta Therapeutics Inc (NASDAQ:SRPT).
Keep Reading →
July 15 - News - Comments
Whether those moves are up or down is hard to tell.
Keep Reading →
July 15 - News - Comments
The tech-heavy NASDAQ Composite (INDEXNASDAQ:.IXIC) might be the only of the U.S.'s three primary indexes not to reach all-time highs in 2013, but it's by far the best performer...
Keep Reading →
July 15 - News - Comments
Ever since the Supreme Court upheld the Patient Protection and Affordable Care Act (nearly in its entirety) last June, we've been examining nearly every facet of the transformative...
Keep Reading →
July 15 - News - Comments
For the last few weeks, there has been a heated debate regarding the success or lack thereof from biotechnology company Amarin Corporation plc (ADR) (NASDAQ:AMRN)'s new product...
Keep Reading →
July 10 - News - Comments
Last November, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing that deep-value...
Keep Reading →
July 5 - News - Comments
A new drug in the fight against cancer is certainly an exciting and welcome development.
Keep Reading →
June 17 - News - Comments
How can you double your investment literally overnight? Buy stocks of the right biotech companies.
Keep Reading →
June 13 - News - Comments
A 2011 Nobel Prize in Physiology and Medicine is certainly impressive. Using a novel cancer treatment on yourself is both impressive and courageous. Dr.
Keep Reading →
June 10 - News - Comments
Dendreon Corporation (NASDAQ:DNDN) was in 13 hedge funds' portfolio at the end of March.
Keep Reading →
June 6 - News - Comments
To most stock holders, hedge funds are seen as underperforming, old financial tools of years past.
Keep Reading →
June 3 - News - Comments
As we've learned over the past few years, getting a drug approved by the Food and Drug Administration is just half the battle in the biotech sector.
Keep Reading →
May 31 - News - Comments
If the JPMorgan Healthcare Conference in January is the mecca of all health-care events during the year, then the American Society of Clinical Oncology's annual meeting in Chicago...
Keep Reading →
May 28 - News - Comments
Huge fortunes are won and lost in the world of biotech nearly every week. For those new to this world, it can appear both alluring and scary.
Keep Reading →
May 22 - News - Comments
Last November, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing that deep-value...
Keep Reading →
May 16 - News - Comments
Here at The Motley Fool, we firmly believe that buying business over the long haul gives investors the best chance for succeeding in the stock market.
Keep Reading →
May 13 - News - Comments
Let's start with Ruckus Wireless Inc (NYSE:RKUS).
Keep Reading →
May 12 - News - Comments
Where have we heard the fourth-quarter-comeback plan before? Oh yes, from Johnson's predecessor who issued 2011 revenue guidance of $350 million to $400 million, with half of ...
Keep Reading →
May 9 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
May 9 - News - Comments
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has faced the affects of bad press more than once in the past.
Keep Reading →
May 8 - News - Comments
There are some vaccine companies that have game changing technologies to target different types of cancer.
Keep Reading →
May 7 - News - Comments
On Thursday, Dendreon Corporation (NASDAQ:DNDN) will release its latest quarterly results.
Keep Reading →
May 7 - News - Comments
Let's start at the top with MAKO Surgical Corp. (NASDAQ:MAKO). The leading player in orthopedic robotics took a hit last year as sales for its RIO platform slowed.
Keep Reading →
May 6 - News - Comments
After around 70 years of investing, Warren Buffett has undoubtedly emerged as one of the great investors all of time, but also one of the pickiest.
Keep Reading →
April 25 - News - Comments
Is Clovis Oncology Inc (NASDAQ:CLVS) the right investment to pursue these days? The best stock pickers are taking a pessimistic view.
Keep Reading →
April 15 - News - Comments
As I noted six weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 10 - News - Comments
If you'd ask most traders, hedge funds are perceived as underperforming, outdated investment tools of years past.
Keep Reading →
April 5 - News - Comments
The immune system doesn't generally attack tumors on its own. Immune cells are designed to attack foreign invaders but leave the human cells alone.
Keep Reading →
March 31 - News - Comments
I haven't ever heard him say it directly, but it's pretty clear that Warren Buffett has no interest in buying biotech companies.
Keep Reading →
March 31 - Hedge Funds - Comments
